Label-free cell phenotypic assessment of the biased agonism and efficacy of agonists at the endogenous muscarinic M3 receptors.
BACKGROUND
Efficacy describes the property of a ligand that enables the receptor to change its behavior towards the host cell, while biased agonism defines the ability of a ligand to differentially activate some of the vectorial pathways over others mediated through the receptor. However, little is known about the molecular basis defining the efficacy of ligands at G protein-coupled receptors. Here we characterize the biased agonism and cell phenotypic efficacy of seven agonists at the endogenous muscarinic M3 receptors in six different cell lines including HT-29, PC-3, HeLa, SF268, CCRF-CEM and HCT-15 cells.


METHODS
Quantitative real-time PCR and multiple label-free whole cell dynamic mass redistribution (DMR) assays were used to determine the functional muscarinic receptors in each cell line. DMR pathway deconvolution assay was used to determine the pathway biased activity of the muscarinic agonists. Operational agonism model was used to quantify the pathway bias, while macro-kinetic data reported in literature was used to analyze the biochemical mechanism of action of these agonists.


RESULTS
Quantitative real-time PCR and ligand pharmacology studies showed that all the native cell lines endogenously express functional M3 receptors. Furthermore, different agonists triggered distinct DMR signals in a specific cell line as well as in different cell lines. DMR pathway deconvolution using known G protein modulators revealed that the M3 receptor in all the six cell lines signals through multiple G protein-mediated pathways, and certain agonists display biased agonism in a cell line-dependent manner. The whole cell efficacy and potency of these agonists were found to be sensitive to the assay time as well as the cell background. Correlation analysis suggested that the whole cell efficacy of agonists is correlated well with their macro-dissociation rate constants.


CONCLUSIONS
This study implicates that the endogenous M3 receptors are coupled to multiple pathways, and the muscarinic agonists can display distinct biased agonism and whole cell phenotypic efficacy.
Biochemical Technologies, Science and Technology Division, Corning Incorporated, Corning, NY 14831, United States.
Huayun
H
Deng
Haiyan
H
Sun
Ye
Y
Fang
D002460:Cell Line; D045744:Cell Line, Tumor; D006801:Humans; D008024:Ligands; D018721:Muscarinic Agonists / Q000494:pharmacology*; D010641:Phenotype; D060888:Real-Time Polymerase Chain Reaction; D043587:Receptor, Muscarinic M3 / Q000819:agonists* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*; D013997:Time Factors
D008024:Ligands; D018721:Muscarinic Agonists; D043587:Receptor, Muscarinic M3; D043562:Receptors, G-Protein-Coupled
Biased agonism; DMR; Drug residence time; Dynamic mass redistribution; Efficacy; G protein-coupled receptor; GPCR; HBSS; Hanks' balanced salt solution; Muscarinic M(3) receptor; RT-PCR; RWG; dynamic mass redistribution; real time polymerase chain reaction; resonant waveguide grating